Resistant Hypertension

New data showed that in-hospital mortality among patients with COVID-19 was nearly twice as high in those with a history of heart failure. A report on the data was the top story in cardiology last week.

A 4-month cardiac rehab program for treatment-resistant hypertension focused on diet, exercise and weight loss conferred greater improvement in both in-office and 24-hour ambulatory BP compared with a single educational session.

Ultrasound renal denervation for patients with triple-therapy resistant hypertension successfully lowered 24-hour ambulatory BP compared with those who underwent a sham procedure, a speaker reported.

Results from the Global SYMPLICITY Registry found that renal denervation conferred consistent BP reduction in patients with high-risk comorbidities regardless of their atherosclerotic CVD risk score.

The problem of hypertension is a multifaceted one. Many factors contribute to the increasing global burden of hypertension. Cardiology Today asked some of the nation’s leading experts on hypertension to glean their thoughts on the most critical issues facing patients and clinicians in that area.

SAN FRANCISCO — Cardiac neuromodulation therapy resulted in significant reductions in systolic BP at 6 months in patients with persistent hypertension and an indication for a pacemaker, according to data from the MODERATO II study presented at TCT 2019.

PHILADELPHIA — Concomitant use of the potassium binder patiromer enabled more patients with resistant hypertension and advanced chronic kidney disease to continue treatment with spironolactone, with less hyperkalemia, according to new data from the AMBER trial presented at the Heart Failure Society of America Scientific Meeting.